Accera, a privately held biotechnology company, discovers and develops breakthroughs in treating central nervous systems disorders. Accera's new and novel therapeutic approaches positively impact patients with neurodegenerative disorders, who are in need of effective, well-tolerated treatments, and their families. Through its proprietary scientific platform, Accera is developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells.
Axona® is available by prescription for the clinical dietary management of mild-to-moderate Alzheimer's disease. A recently published, peer-reviewed scientific paper suggests that daily administration of Axona can help improve cognition and memory in patients with mild-to-moderate Alzheimer's disease, click here. For healthcare professionals and caregivers interested in learning more about Axona, please click here.